Exabis Library
Welcome to the e-CCO Library!
P376: Clinical effectiveness of vedolizumab in a tertiary care cohort of IBD patients
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P376: Effects of IV vedolizumab on health-related quality of life and work productivity in patients with Crohn’s disease: results from the Phase 3b VERSIFY trial
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P376: Efficacy of ozanimod in vedolizumab-exposed patients with ulcerative colitis: a phase 3 True North post hoc analysis
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P376: Improving stress and fatigue in a real-world setting among patients with Inflammatory Bowel Disease through a digital platform
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P376: Switching from intravenous to subcutaneous vedolizumab maintenance treatment; feasibility, safety and clinical outcome
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P376: Therapy refractory ulcerative colitis patients may benefit from appendectomy: early result from the PASSION study
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P377 Risk factors of rectal amputation for Crohn’s disease with perianal lesion
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P377: Changes over time in the Lémann Index and the Inflammatory Bowel Disease-Disability Index in patients with Crohn's disease
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P377: Clinical strategies based on patient-reported outcomes and physicians’ preferences to monitor biological therapy in inflammatory bowel disease
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P377: Complications related to varicella zoster virus infection in patients with inflammatory bowel disease in the pre-JAK inhibitors era: A prospective study
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P377: Evaluation of the pharmacokinetic profiles of SB5 and reference adalimumab
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P377: Impact of moderate-to-severe endoscopic disease criteria on endoscopic response, endoscopic remission, and deep remission in patients receiving ustekinumab or adalimumab in the SEAVUE study
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P377: Inadequate response with advanced therapies in real-world patients with Ulcerative Colitis – Results of a German claims database study
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P377: Serum adalimumab trough levels required for mucosal healing during maintenance therapy in patients with Crohn’s disease
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P378 Mucosal healing is achieved in most of the inflammatory bowel disease patients in clinical remission with vedolizumab: a real-life single-centre experience
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P378: Changes in Simplified Endoscopic Score for Crohn’s disease (SES-CD) during a 16-week induction treatment with upadacitinib: analysis of the randomised controlled CELEST study
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P378: Immunisation practices for hepatitis B and response to vaccination in Greek patients with inflammatory bowel disease
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P378: Oxidative status and antioxidant capacity in children and adults with IBD: preliminary results of the OxIBDiet trial
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P378: Pharmacokinetics of Vedolizumab and Ustekinumab in pregnant women with Inflammatory Bowel Disease and their infants exposed in-utero
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P378: Rectal bleeding and stool frequency improvement with tofacitinib dose escalation to 10 mg BID in patients with Ulcerative Colitis following loss of response on tofacitinib 5 mg BID maintenance therapy: Results from OCTAVE Open
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM